Facebook
Facebook
This 2009 NCDEU Abstract Session was published in October 2009 and is eligible for AMA PRA Category 1 Credit™ through April 30, 2010. The latest review of this material was September 2009.
To obtain credit for this activity, study the material and complete the CME Posttest and Evaluation.
After completing this educational activity, you should be able to:
This special 2009 NCDEU Annual Meeting Abstract Session was developed for CME credit designation on the basis of our assessment of the needs of Web site visitors, with the purpose of providing visitors with a curriculum of abstracts on a variety of topics.
The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The CME Institute of Physicians Postgraduate Press, Inc., designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The presenters for this CME activity and the CME Institute staff were asked to complete a statement regarding all relevant personal financial relationships between themselves and their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. No member of the CME Institute staff reported any relevant personal financial relationships. Financial disclosures from the presenters are as follows:
Dr Bernardo is a consultant for Bristol-Myers Squibb and Wyeth, and has received honoraria from Janssen-Cilag, Eli Lilly, AstraZeneca, Pfizer, Synthelabo, and GlaxoSmithKline.
Dr Botts is a member of the advisory board for Eli Lilly Pharmacy.
Dr Correll is a consultant for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Cephalon, Medicus, Otsuka, Supernus, Pfizer, Vanda, and Schering-Plough; has received honoraria from Ortho-McNeil and Janssen; and is a member of the speakers/advisory boards for AstraZeneca, Bristol-Myers Squibb, Otsuka, and Pfizer.
Dr Kirkpatrick received consulting and/or speaking fees from Pfizer, Organon, AstraZeneca, Wyeth, Eli Lilly, Bristol-Myers Squibb, Cephalon, and Solvay.
Dr Miller has received grant/research support from the University of Oulu, Finland, and Lundbeck.
Drs Bonetti, Conigliaro, Fernandez-Egea, Gallego, Garcia-Rizo, Liu, and Talbert have no personal financial relationships to disclose relative to this presentation.
In this 2009 NCDEU Abstract Session, participants may be presenting investigational information about pharmaceutical agents that is outside US Food and Administration–labeling. This information is intended solely as continuing medical education and is not intended to promote off-label use of any of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
This 2009 NCDEU Abstract Session has been reviewed for accuracy and fair balance by a selection committee of the American Society of Clinical Psychopharmacology (ASCP), and a member of the External CME Advisory Board has reviewed this poster session to determine whether the material is evidence-based and objective.
This 2009 NCDEU Abstract Session is derived from the 49th Annual NCDEU Meeting, which was held June 29–July 2, 2009, in Hollywood, Florida, and was independently developed by the CME Institute of Physicians Postgraduate Press, Inc., the National Institute of Mental Health (NIMH), and the ASCP. The opinions expressed herein are those of the presenters and do not necessarily reflect the opinions of the CME provider and publisher, the NIMH, or the ASCP.
Psychiatrist.com Home
Keyword Search